53P Real-world outcomes of first-line pembrolizumab (Pem) for metastatic non-small cell lung cancer (mNSCLC) with ≥50% expression of programmed cell death-ligand 1 (PD-L1): A multicentre retrospective study

Saved in:
Bibliographic Details
Published in:Journal of thoracic oncology 2023-04, Vol.18 (4), p.S72-S73
Main Authors: Perea, J., Gómez, E., Escrivá, C., Pellicer, A.V., Rodriguez, P. Llor, Iranzo, J., Vidal, O.J. Juan, Sanchez, J. García, Montagud, G. Suay, Míco, A. Ferrero, Diaz, I. Linares, Sepúlveda, N. Gómez, Hernández, E. Soria, Gallego, J. Esteve, Carrasco, C., Gaudens, P. Capdevila
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1556-0864
DOI:10.1016/S1556-0864(23)00307-6